compound 1a [WO2021204952A1]   Click here for help

GtoPdb Ligand ID: 11928

Antimalarial Ligand
Compound class: Synthetic organic
Comment: Compound 1a is from a series of novel tetrahydroisoquinoline derivatives, with antimalarial activity, claimed in patent WO2021204952A1 [1]. Antimalarial potency for this series is predominantly associated with the (+) enantiomer.

The Malaria tab on this ligand page provides additional curator comments of relevance to the Guide to MALARIA PHARMACOLOGY.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 1
Rotatable bonds 8
Topological polar surface area 95.32
Molecular weight 524.15
XLogP 4.99
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES N#Cc1cc(ccc1F)NC(=O)[C@@H]1[C@@H](c2ccc(nc2)OC2CC2)N(CC(F)(F)F)C(=O)c2c1cccc2
Isomeric SMILES C1CC1Oc1ncc(cc1)[C@@H]1[C@H](c2ccccc2C(=O)N1CC(F)(F)F)C(=O)Nc1cc(c(cc1)F)C#N
InChI InChI=1S/C27H20F4N4O3/c28-21-9-6-17(11-16(21)12-32)34-25(36)23-19-3-1-2-4-20(19)26(37)35(14-27(29,30)31)24(23)15-5-10-22(33-13-15)38-18-7-8-18/h1-6,9-11,13,18,23-24H,7-8,14H2,(H,34,36)/t23-,24+/m0/s1
InChI Key KYICPNWURYGJCB-BJKOFHAPSA-N
Guide to Malaria Pharmacology Comments
A patent search suggests that the back-up series for (+)-SJ733, being developed by the University of Kentucky in partnership with MMV, may be covered by patent WO2021204952 [1]. Compound 1a has similar in vitro asexual blood stage potency to (+)-SJ733 together with significantly improved metabolic stability.

Potential Target/Mechanism Of Action: an increase of cytosolic sodium concentration following treatment with compound 1a is consistent with inhibition of Plasmodium non-SERCA-type Ca2+-transporting P-ATPase (PfATP4) [1].